Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 22Active not recruiting 10Recruiting 5Unknown 2Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 723Neoplasms 461Prostatic Neoplasms 398Carcinoma, Non-Small-Cell Lung 388Lung Neoplasms 311Leukemia, Myeloid, Acute 301Multiple Myeloma 270Colorectal Neoplasms 243Neoplasm Metastasis 240Pancreatic Neoplasms 238Leukemia 235Melanoma 217Lymphoma 213Precursor Cell Lymphoblastic Leukemia-Lymphoma 204Brain Neoplasms 195Recurrence 178Head and Neck Neoplasms 177Lymphoma, Non-Hodgkin 174Myelodysplastic Syndromes 168Leukemia, Lymphocytic, Chronic, B-Cell 168Ovarian Neoplasms 160Carcinoma, Hepatocellular 154Glioblastoma 149Carcinoma, Renal Cell 137Rectal Neoplasms 134Colonic Neoplasms 129Lymphoma, Large B-Cell, Diffuse 125Lymphoma, Follicular 125Hodgkin Disease 116Squamous Cell Carcinoma of Head and Neck 109

Interventions

Crizotinib 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × Urethral Neoplasms × Clear all
NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

University of Chicago

Phase 2 Terminated
32 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Wake Forest University Health Sciences

Phase 2 Terminated
8 enrolled 16 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡